Dual Erb B Inhibition in Oesophago-gastric Cancer (DEBIOC): A phase I dose escalating safety study and randomised dose expansion of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophagogastric adenocarcinoma

Anne Thomas*, Pradeep S. Virdee, Martin Eatock, Simon R. Lord, Stephen Falk, D. Alan Anthoney, Richard C. Turkington, Matthew Goff, Leena Elhussein, Linda Collins, Sharon Love, Joanna Moschandreas, Mark R. Middleton

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)
24 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Dual Erb B Inhibition in Oesophago-gastric Cancer (DEBIOC): A phase I dose escalating safety study and randomised dose expansion of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophagogastric adenocarcinoma'. Together they form a unique fingerprint.

Medicine & Life Sciences